WINDWARD BIO GROUP AG Form 424B4 — Nov 13, 2026
Windward Bio Group AG, a Swiss clinical-stage biotech developing ultra-long-acting antibodies for asthma, COPD and atopic dermatitis, priced its IPO at $17.00 per share, offering 10,294,117 common shares for gross proceeds of approximately $175.0 million. The shares will list on Nasdaq under the symbol WWB, with Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank as underwriters. Concurrent with the IPO, Sanofi has agreed to purchase 1,532,691 common shares plus pre-funded warrants for an aggregate $50.0 million at the same $17.00 price, expected to close alongside the offering.
Key figures
- Gross Proceeds
- 174999989
- Offering Price
- 17
- Shares Offered
- 10294117
- Greenshoe
- 1544117
- Net loss fy2025
- $48.3 million
- Net loss h1 2026
- $42.6 million
- Cash june 30 2026
- $207.3 million
- Reverse share split
- 3-for-2, effective November 6, 2026
- Net proceeds estimate
- $203.8 million (or $228.0 million if greenshoe fully exercised)
- Pro forma cash as adjusted
- $411.1 million
- Concurrent private placement
- $50.0 million Sanofi purchase of 1,532,691 shares plus pre-funded warrants on 1,408,485 shares
- Preliminary cash sept 30 2026
- $181.8 million
- Accumulated losses june 30 2026
- $93.2 million
- Underwriting discount per share
- 1.19
- Total shares outstanding post offering
- 58,038,748 (or 59,582,865 with full greenshoe)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.